Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

SuppreMol brings in €15.5mm through Series C round

03 Dec 2010

Executive Summary

SuppreMol GMBH (antibodies for autoimmune diseases) raised €15.5mm ($20.25mm) through its Series C round, which was co-led by MIG AG and BioMedPartners AG. New investor FCP Biotech Holding also participated, along with returning backers Santo Holding, KfW Mittelstandsbank, Bayern Kapital, and Max-Planck-Gesellschaft. Proceeds from the financing will be put towards SuppreMol's Phase I/IIa candidate SM101 for primary immune thrombocytopenia and systemic lupus erythematosus, and for continued development of a preclinical monoclonal antibody.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By